Miscellaneous Neurodegenerative Disoders

Hizentra Approved for Chronic Inflammatory Demyelinating Polyneuropathy

By March 16, 2018

The PATH study demonstrated that the percentage of patients experiencing CIDP relapse or withdrawal for any other reason during SCIg treatment was significantly lower with Hizentra

Botox Treatment Efficacy Examined for Facial Synkinesis

September 28, 2017

The researchers conducted a prospective cohort study involving 23 patients who underwent treatment for facial synkinesis with botulinum toxin over multiple treatment cycles

Orphan Drug Designation Granted to ALS Treatment

By September 19, 2017

A Phase 2 randomized, double-blind, placebo-controlled trial of AMX0035 titled CENTAUR (nct03127514) has begun with 132 ALS participants enrolled.

Anti-PD-1 Therapy Tied to Neurological Adverse Events

September 11, 2017

The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.

Austedo Approved for the Treatment of Tardive Dyskinesia

By August 31, 2017

Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was initially approved to treat Huntington's chorea in April 2017.

fMRI, EEG May Benefit Traumatic Brain Injury Patients in the ICU

July 24, 2017

Bedside exams often miss subtle signs Early detection of consciousness and brain function in the intensive care unit could allow families to make more informed decisions about the care of loved ones," co-lead author Brian Edlow.

Study Aims to "Set the Record Straight" on PPIs and Dementia

By July 20, 2017

After multivariable adjustment - which included duration of chronic medical conditions - a modest statistically significant association was only seen for psychomotor speed and attention.

PANS/PANDAS Treatment Guidelines Released

By July 20, 2017

"Immunomodulatory therapy should be considered early, because NSAIDs or a short course of oral corticosteroids may be sufficient for symptom remission in recent-onset cases, whereas those with long-standing symptoms often require more intensive and prolonged immunotherapeutic interventions," the authors write.

Maternal Antidepressant Use and Offspring Disability: What's the Link?

July 13, 2017

No significant association for use of antidepressant in pregnancy, child's intellectual disability

Switching from Tetrabenazine to Deutetrabenazine Evaluated in Huntington's Disease

By July 11, 2017

Study authors concluded that patients taking tetrabenazine three times daily can safely be converted to deutetrabenazine twice daily, while maintaining chorea control.

Certain Diets Linked to Improved Cognitive Function in Older Adults

July 10, 2017

The researchers found that in fully adjusted models, participants with mid and high MedDiet scores were less likely to have poor cognitive performance than those with low scores.

The Smartphone 'Brain Drain': Your Phone May Impair Cognitive Capacity

June 28, 2017

These cognitive costs were highest for those with the highest dependence on smartphones. This smartphone-induced brain drain can have practical implications for decision-making and consumer welfare.

Are U.S. Drinking Guidelines Too Liberal?

June 08, 2017

Overall, moderate drinkers were more than 3 times as likely as abstainers to show abnormal levels of atrophy in the right hippocampus. That included people who averaged 14 to 21 units of alcohol each week.

Ideal Magnesium Sulfate Dose ID'd for Fetal Neuroprotection

By June 07, 2017

The analysis found that the simulated maternal serum concentration associated with the lowest probability of infant cerebral palsy was 4.1mg/dL, while the simulated total administered magnesium dose associated with the lowest probability of delivering an infant with cerebral palsy was 64g.

Does Opioid Therapy Benefit Patients with Polyneuropathy?

May 23, 2017

The authors examined long-term opioid therapy, defined by 1 or multiple consecutive opioid prescriptions resulting in 90 days or more of opioid use.

Early Intervention with Radicava Beneficial in ALS

By May 19, 2017

There was also an approximate 58% relative risk reduction in death or certain disease progression events in the 48-week Radicava group versus those given placebo initially.

Inotersen Shows Promise in Phase 3 Familial Amyloid Polyneuropathy Study

By May 15, 2017

Ionis announced positive results from the Phase 3 study of inotersen (IONIS-TTRRx) for the treatment of familial amyloid polyneuropathy (FAP), now referred to as hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).

Trigriluzole Fast Tracked for Rare Neurodegenerative Disorder

By May 15, 2017

The FDA has granted Fast Track designation to trigriluzole (BHV-4157; Biohaven) for the potential treatment of Spinocerebellar Ataxia (SCA), a rare and debilitating neurodegenerative disorder.

Handheld Device Use Tied to Delayed Development in Infants

May 05, 2017

Specifically, for each 30-minute increase in handheld screen time, there was a 49% increased risk of expressive speech delay.

Artificial 'Womb' Could Potentially Up Survival of Extremely Premature Infants

By April 26, 2017

Five lamb fetuses of 105 to 108 days of gestation were run for 25-28 days, and three fetuses of 115 to 120 days of gestation were run for 20-28 days.

Communication Training May Help Cut Nursing Home Antipsychotic Use

April 21, 2017

Researchers found that nursing homes enrolled in the OASIS program had a 7.6% drop in antipsychotic prescriptions, compared with a 3.9% decline at the other nursing homes.

Does Low-Dose Aspirin Protect Against Cognitive Decline?

By April 20, 2017

The analysis showed that over a median of 6 years, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment.

Insulin Resistance-, High Fasting Levels May Impact Cognition

April 10, 2017

The researchers found that higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance (P=0.0002 for both) and of a greater decline in verbal fluency over follow-up (P=0.004 for both).

Austedo Approved for Huntington's Disease

By April 04, 2017

Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first deuterated product approved by the FDA.

Possible Intervention Route ID'd for Chronic Tension-Type Headache

March 30, 2017

Researchers found that changes in neuroendocrine hormones were seemingly involved in symptoms of chronic tension-type headaches.

Neuralink Aims to Merge Computers with the Human Brain

By March 29, 2017

Mr. Musk is calling the brain implant 'neural lace', and in addition to possibly giving humans artificial intelligence, it may also be used to improve memory function.

Concerns Raised Over Commonly Prescribed OAB Drug

March 28, 2017

Among elderly patients, oxybutynin was frequently prescribed and continued; incidence, 27.3%; prevalence, 33.2%.

VIDEO: Certain Drugs May Improve Cognitive Abilities in Chess Players

March 10, 2017

To examine any potential cognitive improvement, researchers conducted a crossover study of modafinil, methylphenidate, caffeine and placebo.

FDA Warns of Unapproved Treatment for Autonomic Dysfunction

By March 09, 2017

Serious side effects, including one fatality, have been reported.

Donepezil May Worsen Outcomes for Certain Patients with MCI

March 09, 2017

Donepezil should not be prescribed to patients with mild cognitive impairment without first giving them a genetic test, according to research published recently in the Journal of Alzheimer's Disease.